Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes

Journal of Internal Medicine

Volumn 269, Issue 3, 2011, Pages 322-332

  Luotola, K ^a   Pietila A ^b   Zeller, T ^c   Moilanen, L ^d   Kahonen M ^e   Nieminen, M S ^a   Kesaniemi Y A ^f   Blankenberg, S ^c   Jula, A ^b   Perola, M ^b,g   Salomaa, V ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Diabetes; Epidemiology; IL 1 genes; Inflammation; Interleukin 1 receptor antagonist

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEX FACTORS;

EID: 79951711058     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02294.x     Document Type: Article

References (27)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
2. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48: 1038-50.
3. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
4. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-50.
5. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-8.
6. Carstensen M, Herder C, Kivimaki M et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010; 59: 1222-7.
7. Rafiq S, Stevens K, Hurst AJ et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 2007; 8: 344-51.
8. Melzer D, Perry JR, Hernandez D et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008; 4: e1000072.
9. Reiner AP, Wurfel MM, Lange LA et al. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol 2008; 28: 1407-12.
10. Luotola K, Paakkonen R, Alanne M et al. Association of variation in the interleukin-1 gene family with diabetes and glucose homeostasis. J Clin Endocrinol Metab 2009; 94: 4575-83.
11. Luotola K, Pietila A, Alanne M et al. Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes. Metabolism 2010; 59: 1520-7.
12. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002; 87: 1184-8.
13. Aromaa A, Koskinen S. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Helsinki: Publications of the National Public Health Institute, 2004; B12.
14. Vartiainen E, Laatikainen T, Peltonen M et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39: 504-18.
15. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
17. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from: [accessed on 26 April 2010].
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
19. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-9.
20. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-9.
21. Marculescu R, Endler G, Schillinger M et al. Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. Diabetes 2002; 51: 3582-5.
22. Ruotsalainen E, Salmenniemi U, Vauhkonen I et al. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 2006; 29: 2714-20.
23. Maedler K, Sergeev P, Ehses JA et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004; 101: 8138-43.
24. Herder C, Brunner EJ, Rathmann W et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32: 421-3.
25. Salomaa V, Havulinna A, Saarela O et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 2010; 5: e10100.
26. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-904.
27. Thorand B, Baumert J, Kolb H et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007; 30: 854-60.